

Supporting Information

Potent CXCR4 Antagonists Containing Amidine-type Peptide Bond Isosteres

Eriko Inokuchi,[†] Shinya Oishi,^{*,†} Tatsuhiko Kubo,[†] Hiroaki Ohno,[†] Kazuya Shimura,[‡]
Masao Matsuoka[‡] and Nobutaka Fujii^{*,†}

[†]*Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan*

[‡]*Institute for Virus Research, Kyoto University, Sakyo-ku, Kyoto 606-8507, Japan*

Table of Contents

Experimental Section	S2
References.....	S14
HPLC chromatograms (Figures S1-S3).....	S15
Data of biological evaluations (Figure S4)	S17
NMR spectra	S18

Experimental Section

General Methods. All moisture-sensitive reaction were performed using syringe-septum cap techniques under an argon atmosphere and all glassware was dried in an oven at 80 °C for 2 h prior to use. Optical rotations were measured with a JASCO P-1020 polarimeter. For flash chromatography, Wakogel C-300E or Chromatorex was employed. For analytical HPLC, a Cosmosil 5C18-ARII column (4.6 x 250 mm, Nacalai Tesque Inc., Kyoto, Japan) was employed with a linear gradient of CH₃CN containing 0.1 % (v/v) TFA at a flow rate of 1 mL/min on Shimadzu LC-20ADvp (Shimadzu corporation, Ltd, Kyoto, Japan). Preparative HPLC was performed using a Cosmosil 5C18-ARII column (20 x 250 mm, Nacalai Tesque Inc.) with a linear gradient of CH₃CN containing 0.1 % (v/v) TFA at a flow rate of 8 mL/min on Shimadzu LC-6AD (Shimadzu corporation, Ltd). ¹H NMR spectra were recorded using a JEOL ECA-500 spectrometer, and chemical shifts are reported in δ (ppm) relative to TMS (in DMSO-*d*₆) as internal standard. ¹³C NMR spectra were recorded using a JEOL ECA-500 spectrometer and referenced to the residual DMSO signal. Chemical shifts were reported in parts per million with the residual solvent peak used as an internal standard. ¹H NMR spectra are tabulated as follows: chemical shift, multiplicity (br = broad, s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet), number of protons, and coupling constant(s). Exact mass (HRMS) spectra were recorded on a JMS-HX/HX 110A mass spectrometer. The purity of the peptides for bioassay was calculated as >95% by HPLC on a Cosmosil 5C18-ARII analytical column at 220 nm absorbance (Figure S3). Resin and Fmoc-protected amino acids were purchased from Watanabe Chemical Industries, Ltd (Hiroshima, Japan) or Kokusan Chemical Co. Ltd. (Kanagawa, Japan). All the other chemicals were purchased from either Nacalai Tesque Inc. (Kyoto, Japan) or Sigma-Aldrich JAPAN (Tokyo, Japan).

H₂N-O-(2-Cl)Trt resin (8). 2-Chlorotrityl resin chloride (loading: 1.31 mmol/g, 76.3 mg) was reacted with Fmoc-NHOH (128 mg, 0.500 mmol) and pyridine (810 μL, 1.00 mmol) in THF (800 μL) at 60 °C for 6 h. The solution was removed by filtration and the resulting resin was washed with the solution of DMF-(*i*-Pr)₂NEt-MeOH (17:2:1). The Fmoc-protecting group was removed by treating the resin with a DMF-piperidine solution (80:20, v/v). The loading was determined by measuring at 290 nm UV absorption of the piperidine-treated sample: 0.900 mmol/g, 89%.

Fmoc-3-(2-naphthyl)alaninal (9b). Aldehyde **9b** was prepared from Fmoc-Nal-NMe(OMe) by the literature procedure.¹ The crude product was used for the next step without further purification.

General procedure for the preparation of peptide aldoxime 12:

H-Gly-D-Tyr(*t*-Bu)-Arg(Pbf)-Arg(Pbf)-Nal-aldoxime (12b). The solid supported hydroxyamine **8** (loading: 0.900 mmol/g, 91.6 mg, 0.0820 mmol) was reacted with Fmoc-3-(2-naphthyl)alaninal **9b** (0.500 mmol) in dichloroethane (700 μ L), HC(OMe)₃ (500 μ L) and AcOH (1 μ L) at 60 °C for 2 h. The solution was removed by filtration and the resulting resin was washed with DMF to afford resin **10b**. The peptide-resin **11b** was manually constructed using Fmoc-based solid-phase synthesis on resin **10b**. The Fmoc-protecting group was removed by treating the resin with a DMF–piperidine solution (80:20, v/v). Fmoc-protected amino acid (0.500 mmol, 6.1 equiv) was successively coupled using DIC (77 μ L, 0.500 mmol, 6.1 equiv) in the presence of HOBt (77 mg, 0.500 mmol, 6.1 equiv) to give resin **11b**. *t*-Bu ether for Tyr and 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl (Pbf) for Arg were employed for side-chain protection. Resin **11b** was treated with TFA–TIS–CH₂Cl₂ (20 mL, 0.5:0.1:99.4) at room temperature for 1.5 h. After removal of the resin by filtration, the filtrate was concentrated under reduced pressure to give off a crude peptide aldoxime **12b** as a yellow oil. The crude product was used for the next step without further purification.

H-D-Tyr(*t*-Bu)-Arg(Pbf)-Arg(Pbf)-Nal-Gly-aldoxime (12a). By use of a procedure identical with that described for the preparation of **12b** from **9b**, the reaction of Fmoc-glycinal **9a** gave the title compound **12a**.

H-Gly-D-Tyr(*t*-Bu)-Arg(Pbf)-Arg(Pbf)-D-Nal-aldoxime (12c). By use of a procedure identical with that described for the preparation of **12b** from **9b**, the reaction of Fmoc-D-3-(2-naphthyl)alaninal **9c** gave the title compound **12c**.

H-Nal-Gly-D-Tyr(*t*-Bu)-Arg(Pbf)-Arg(Boc)₂-aldoxime (12d). By use of a procedure identical with that described for the preparation of **12b** from **9b**, the reaction of di-Boc-protected Fmoc-arginal **9d** gave the title compound **12d**.

H-Arg(Pbf)-Nal-Gly-D-Tyr(*t*-Bu)-Arg(Boc)₂-aldoxime (12e). By use of a procedure identical with that described for the preparation of **12b** from **9b**, the reaction of di-Boc-protected Fmoc-arginal **9d** gave the title compound **12e**.

H-Arg(Pbf)-Arg(Pbf)-Nal-Gly-D-Tyr(*t*-Bu)-aldoxime (12f). By use of a procedure identical with that described for the preparation of **12b** from **9b**, the reaction of *t*-Bu-protected Fmoc-D-tyrosinal **9f** gave the title compound **12f**.

H-Arg(Pbf)-Arg(Pbf)-Nal-Gly-Tyr(*t*-Bu)-aldoxime (12g). By use of a procedure identical with that described for the preparation of **12b** from **9b**, the reaction of *t*-Bu-protected Fmoc-tyrosinal **9g** gave the title compound **12g**.

General Procedure for nitrile oxide-mediated cyclization:

Cyclo[-D-Tyr(*t*-Bu)-Arg(Pbf)-Arg(Pbf)-Nal- ψ [C(=NOH)-NH]-Gly-] (13b). To a solution of peptide aldoxime **12b** in DMF (1 mL) was added *N*-chlorosuccinimide (14.7 mg, 0.100 mmol). The solution was stirred at room temperature overnight, and then DMF (40 mL) and Et₃N (400 μ L) were added. The mixture was stirred at room temperature overnight, and was then concentrated under reduced pressure. The residue was extracted with EtOAc and the extract was washed with brine. The organic layer was dried over Na₂SO₄, and concentrated under reduced pressure to give a yellow oil, which was purified by column chromatography over silica gel with CH₂Cl₂-MeOH (95:5) to give **13b** (41.7 mg, 33% yield from resin **8**) as a yellow oil: $[\alpha]^{26}_D$ -28.1 (*c* 0.105, DMSO); ¹H NMR (500 MHz, DMSO-*d*₆) δ 1.21 (s, 9H), 1.36 (s, 3H), 1.37 (s, 3H), 1.39 (s, 3H), 1.40 (s, 3H), 1.45–1.90 (m, 8H), 1.99 (s, 3H), 2.00 (s, 3H), 2.42 (s, 6H), 2.48 (s, 6H), 2.50 (s, 2H), 2.56 (s, 2H), 2.80–2.96 (m, 8H), 3.16–3.20 (m, 1H), 3.61–3.68 (m, 1H), 3.91–3.98 (m, 1H), 4.13–4.21 (m, 2H), 4.36–4.42 (m, 1H), 5.73–5.79 (m, 1H), 6.38 (br s, 2H), 6.82 (d, *J* = 7.4 Hz, 2H), 7.09 (d, *J* = 7.4 Hz, 2H), 7.36 (d, *J* = 8.3 Hz, 1H), 7.41–7.46 (m, 2H), 7.54 (d, *J* = 9.5 Hz, 1H), 7.65 (s, 1H), 7.74–7.85 (m, 4H), 8.45 (d, *J* = 8.5 Hz, 1H), 8.55–8.60 (m, 1H), 8.86–8.90 (m, 1H), 9.46 (s, 1H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 12.3 (2C), 17.3 (2C), 17.6 (2C), 18.9 (2C), 24.0, 28.2 (2C), 28.3 (2C), 28.4 (2C), 29.5 (4C), 30.8 (3C), 35.8, 42.5, 45.7 (2C), 52.8, 56.6, 77.6, 86.2, 86.3, 116.0, 116.3, 118.5, 123.4, 124.3 (2C), 124.4 (2C), 125.3, 125.9, 127.2, 127.3, 127.4, 127.5, 127.5, 127.8, 129.7, 130.3, 131.4, 131.8, 132.9, 135.7, 136.6, 137.2, 153.7, 156.1, 157.5, 157.9, 158.4, 160.7, 161.5, 162.3, 170.9, 171.5, 179.4; HRMS (FAB) calcd for C₆₆H₈₉N₁₂O₁₂S₂ (MH⁺) 1305.6164; found 1305.6160.

Cyclo[-D-Tyr(*t*-Bu)-Arg(Pbf)-Arg(Pbf)-Nal-Gly- ψ [C(=NOH)-NH]-] (13a). By use of a procedure identical with that described for the preparation of **13b** from **12b**, the peptide aldoxime **12a** was converted into the title compound **13a** (32% yield from **8**). Yellow oil; $[\alpha]^{27}_D$ +4.02 (*c* 0.141, DMSO); ¹H NMR (500 MHz, DMSO-*d*₆) δ 1.25 (s, 9H), 1.32–1.40 (m, 4H), 1.39 (s, 12H), 1.42–1.60 (m, 4H),

1.97–1.99 (m, 6H), 2.43 (s, 6H), 2.48 (s, 6H), 2.93 (d, J = 14.3 Hz, 2H), 2.85–3.00 (m, 6H), 3.82–4.00 (m, 1H), 4.10–4.23 (m, 2H), 4.47–4.60 (m, 1H), 5.30 (d, J = 10.5 Hz, 1H), 6.25–6.45 (br s, 2H), 6.87 (d, J = 8.3 Hz, 2H), 7.12 (d, J = 8.3 Hz, 2H), 7.27 (d, J = 9.0 Hz, 1H), 7.36–7.47 (m, 2H), 7.58 (s, 1H), 7.63–7.70 (m, 1H), 7.74–7.82 (m, 5H), 8.43–8.49 (m, 1H), 9.51 (s, 1H); ^{13}C NMR (125 MHz, DMSO-*d*₆) δ 12.3 (2C), 17.0, 17.2, 17.2 (2C), 17.7, 21.7, 22.3, 22.6, 22.7, 22.8 (3C), 22.9, 23.0, 24.1, 33.3 (3C), 33.4, 33.6, 33.7, 34.7, 35.9, 40.9 (2C), 47.4, 47.6, 82.9, 91.2, 91.4, 121.3 (2C), 121.4 (2C), 128.7 (3C), 128.7, 129.4 (2C), 129.5 (2C), 132.6, 132.6, 132.9, 134.1 (2C), 134.7, 135.2, 136.6 (2C), 136.9, 138.0, 138.3, 139.3, 139.3, 142.4, 160.2 (2C), 162.6, 167.4 (2C), 167.5, 176.1; HRMS (FAB) calcd for C₆₆H₈₉N₁₂O₁₂S₂ (MH⁺) 1305.6164; found 1305.6160.

Cyclo[-D-Tyr(*t*-Bu)-Arg(Pbf)-Arg(Pbf)-D-Nal-ψ[C(=NOH)-NH]-Gly-] (13c). By use of a procedure identical with that described for the preparation of **13b** from **12b**, the peptide aldoxime **12c** was converted into the title compound **13c** (58% yield from **8**). Yellow oil; $[\alpha]^{27}\text{D}$ +44.5 (*c* 0.213, DMSO); ^1H NMR (500 MHz, DMSO-*d*₆) δ 1.21 (s, 9H), 1.21–1.40 (m, 8H), 1.38 (s, 12H), 2.00 (s, 6H), 2.41 (s, 3H), 2.42 (s, 3H), 2.45 (s, 3H), 2.48 (s, 3H), 2.58–2.70 (m, 6H), 2.94 (s, 4H), 3.21 (dd, J = 13.5, 6.2 Hz, 1H), 3.68–3.77 (m, 2H), 3.78–3.85 (m, 2H), 4.04 (dd, J = 12.8, 5.9 Hz, 1H), 4.32–4.38 (m, 1H), 4.78 (dd, J = 14.8, 8.5 Hz, 1H), 6.00–6.08 (m, 1H), 6.27–6.49 (br s, 4H), 6.82 (d, J = 8.0 Hz, 2H), 7.07 (d, J = 8.0 Hz, 2H), 7.29–7.42 (m, 3H), 7.66 (s, 1H), 7.68–7.85 (m, 3H), 7.88–7.98 (m, 2H), 8.00–8.09 (m, 1H), 8.63 (d, J = 6.7 Hz, 1H), 9.84 (s, 1H); ^{13}C NMR (125 MHz, DMSO-*d*₆) δ 12.3 (2C), 17.6 (2C), 19.0 (2C), 25.0, 27.7, 28.3 (2C), 28.5 (2C), 28.6 (2C), 28.7, 29.0, 29.5 (4C), 30.8 (2C), 35.8, 42.5, 48.6 (2C), 54.6, 55.2, 77.7, 79.2, 86.3, 116.3 (2C), 123.6, 124.3 (2C), 124.4 (2C), 125.2, 125.8, 127.3, 127.4, 127.5, 127.5, 127.6, 128.0, 129.5, 131.3, 131.4, 131.5, 131.7, 132.9, 134.2, 136.3, 137.3, 151.1, 153.7, 155.9, 157.5 (2C), 162.3, 169.9, 171.5, 171.9, 172.5, 179.4; HRMS (FAB) calcd for C₆₆H₈₉N₁₂O₁₂S₂ (MH⁺) 1305.6164; found 1305.6150.

Cyclo[-D-Tyr(*t*-Bu)-Arg(Pbf)-Arg(Boc)₂-ψ[C(=NOH)-NH]-Nal-Gly-] (13d). By use of a procedure identical with that described for the preparation of **13b** from **12b**, the peptide aldoxime **12d** was converted into the title compound **13d** (34% yield from **8**). Yellow oil; $[\alpha]^{25}\text{D}$ -7.04 (*c* 0.412, DMSO); ^1H NMR (500 MHz, DMSO-*d*₆) δ 1.22 (s, 9H), 1.28–1.49 (m, 4H), 1.35 (s, 6H), 1.37 (s, 9H), 1.38 (s, 9H), 1.99 (s, 3H), 2.40 (s, 3H), 2.46 (s, 3H), 2.70–2.72 (m, 2H), 2.90–2.98 (m, 6H), 3.38 (s, 2H), 4.16–4.25 (m, 1H), 4.26–4.38 (m, 2H), 4.39–4.60 (m, 3H), 6.76–6.83 (m, 4H), 7.10 (d, J = 6.9 Hz, 1H), 7.40–7.50 (m, 5H), 7.75–7.86 (m, 4H), 8.17–8.25 (m, 4H), 9.58 (s, 1H); ^{13}C NMR (125 MHz, DMSO-*d*₆) δ 12.2, 15.7, 18.9, 27.4 (2C), 27.6 (2C), 27.7 (2C), 28.0 (2C), 28.0 (2C), 28.3 (2C), 28.5,

28.7 (3C), 29.5 (6C), 40.1, 42.5, 77.6, 78.1, 82.9, 86.3 (2C), 116.2, 123.3, 123.4, 124.3, 125.3 (2C), 125.9 (2C), 126.0, 127.3, 127.4, 127.6, 127.8, 129.6, 129.7, 131.4, 131.9, 133.0, 134.1, 134.2, 136.3, 137.3, 149.4, 152.1, 153.5, 155.2, 156.0, 157.4, 163.1, 179.4 (2C); HRMS (FAB) calcd for C₆₃H₈₉N₁₂O₁₃S (MH⁺) 1253.6393; found 1253.6390.

Cyclo[-D-Tyr(t-Bu)-Arg(Boc)₂-ψ[C(=NOH)-NH]-Arg(Pbf)-Nal-Gly-] (13e). By use of a procedure identical with that described for the preparation of **13b** from **12b**, the peptide aldoxime **12e** was converted into the title compound **13e** (40% yield from **8**). Yellow oil; [α]²⁵_D +7.60 (*c* 0.401, DMSO); ¹H NMR (500 MHz, DMSO-*d*₆) δ 1.21 (s, 9H), 1.21–1.25 (m, 4H), 1.34–1.40 (m, 4H), 1.37 (s, 9H), 1.38 (s, 6H), 1.46 (s, 9H), 1.99 (s, 3H), 2.41 (s, 3H), 2.47 (s, 3H), 2.54–2.56 (m, 2H), 2.90–2.97 (m, 4H), 3.05–3.12 (m, 2H), 3.35 (s, 2H), 3.56 (dd, *J* = 16.5, 6.2 Hz, 1H), 3.64–3.72 (m, 1H), 4.38 (dd, *J* = 15.6, 7.7 Hz, 1H), 4.43 (dd, *J* = 14.2, 7.7 Hz, 1H), 4.51 (dd, *J* = 14.9, 8.0 Hz, 1H), 6.12 (d, *J* = 11.3 Hz, 1H), 6.77 (d, *J* = 8.4 Hz, 2H), 6.80–6.86 (m, 1H), 7.02 (d, *J* = 8.3 Hz, 2H), 7.15 (d, *J* = 8.3 Hz, 1H), 7.39 (d, *J* = 8.7 Hz, 1H), 7.43–7.46 (m, 2H), 7.73 (s, 1H), 7.79–7.85 (m, 4H), 8.14 (t, *J* = 5.5 Hz, 1H), 8.25 (t, *J* = 5.9 Hz, 1H), 8.63 (t, *J* = 5.7 Hz, 1H), 9.90 (s, 1H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 12.1, 17.6, 18.9 (2C), 25.2, 27.6 (4C), 28.0 (4C), 28.3 (3C), 28.5 (5C), 29.5 (5C), 42.5, 78.0, 79.2, 82.9 (2C), 86.2, 116.3, 123.3 (2C), 124.3, 125.6, 126.1, 127.3, 127.3, 127.4, 127.5, 127.5, 127.7, 129.6 (2C), 131.4, 131.9, 132.6, 133.0, 134.7, 152.2, 153.3, 155.2, 156.1, 157.5, 162.3, 163.1, 168.2, 169.2, 171.8, 174.7, 179.4; HRMS (FAB) calcd for C₆₃H₈₉N₁₂O₁₃S (MH⁺) 1253.6393; found 1253.6398.

Cyclo[-D-Tyr(t-Bu)-ψ[C(=NOH)-NH]-Arg(Pbf)-Arg(Pbf)-Nal-Gly-] (13f). By use of a procedure identical with that described for the preparation of **13b** from **12b**, the peptide aldoxime **12f** was converted into the title compound **13f** (27% yield from **8**). Yellow oil; [α]²⁶_D -150.9 (*c* 0.103, DMSO); ¹H NMR (500 MHz, DMSO-*d*₆) δ 1.25 (s, 9H), 1.25–1.30 (m, 4H), 1.39 (s, 6H), 1.40 (s, 6H), 1.40–1.80 (m, 4H), 1.98 (s, 6H), 2.40–2.43 (m, 6H), 2.45–2.47 (m, 6H), 2.89–2.95 (m, 8H), 2.50 (s, 2H), 2.57 (s, 2H), 3.13–3.20 (m, 1H), 3.52–3.69 (m, 2H), 4.23–4.25 (m, 1H), 4.50–4.55 (m, 2H), 5.50 (s, 1H), 6.25–6.50 (br s, 2H), 6.83 (d, *J* = 8.2 Hz, 2H), 7.07 (d, *J* = 8.2 Hz, 2H), 7.08–7.15 (m, 1H), 7.35–7.49 (m, 4H), 7.70–7.80 (m, 4H), 8.23–8.27 (m, 1H), 8.27–8.29 (m, 1H), 9.31 (s, 1H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 12.2, 12.3, 12.4, 17.6 (2C), 18.9, 22.1 (2C), 24.0, 28.3, 28.5 (4C), 28.6, 29.0, 29.5 (4C), 30.8, 31.3, 35.8 (3C), 42.4, 45.7 (2C), 77.6, 86.2, 86.3, 116.3, 123.3 (2C), 123.4 (2C), 124.3, 125.9 (2C), 127.3 (2C), 127.4, 127.7 (2C), 129.5 (2C), 129.7 (2C), 131.4, 131.7, 132.9, 133.2, 134.2, 136.4, 137.3, 153.3, 157.1, 157.5, 158.2, 161.5 (2C), 162.3, 168.6, 170.4, 171.7, 179.3; HRMS (FAB) calcd for C₆₆H₈₉N₁₂O₁₂S₂ (MH⁺) 1305.6164; found 1305.6160.

Cyclo[-Tyr(*t*-Bu)- ψ [C(=NOH)-NH]-Arg(Pbf)-Arg(Pbf)-Nal-Gly-] (13g). By use of a procedure identical with that described for the preparation of **13b** from **12b**, the peptide aldoxime **12g** was converted into the title compound **13g** (50% yield from **8**). Yellow oil; $[\alpha]^{27}_D -64.9$ (*c* 0.436, DMSO); ^1H NMR (500 MHz, DMSO-*d*₆) δ 1.26 (s, 9H), 1.26–1.40 (m, 4H), 1.40 (s, 12H), 1.51–1.60 (m, 4H), 1.99 (s, 3H), 2.00 (s, 3H), 2.40 (s, 3H), 2.44 (s, 3H), 2.46 (s, 3H), 2.50 (s, 3H), 2.60–2.67 (m, 1H), 2.71–2.76 (m, 1H), 2.87–2.99 (m, 6H), 3.07–3.14 (m, 1H), 3.16 (s, 2H), 3.17 (s, 2H), 3.19–3.25 (m, 1H), 3.40–3.48 (m, 1H), 3.52–3.58 (m, 1H), 3.65–3.71 (m, 1H), 4.24–4.36 (m, 3H), 4.63–4.68 (m, 1H), 6.22 (d, *J* = 11.6 Hz, 2H), 6.23–6.30 (br s, 2H), 6.83 (d, *J* = 8.3 Hz, 2H), 7.12 (d, *J* = 8.3 Hz, 2H), 7.23 (d, *J* = 10.3 Hz, 1H), 7.32 (d, *J* = 7.4 Hz, 1H), 7.36–7.41 (m, 2H), 7.50–7.55 (m, 1H), 7.60 (s, 1H), 7.72–7.81 (m, 3H), 7.91 (s, 1H), 8.52–8.58 (m, 1H), 10.06 (s, 1H); ^{13}C NMR (125 MHz, DMSO-*d*₆) δ 12.2, 12.3, 17.6, 17.7, 18.9, 19.0, 28.2, 28.3, 28.4 (2C), 28.5 (3C), 29.0, 29.5 (4C), 29.6, 30.1, 30.8, 35.8 (2C), 42.4 (2C), 49.1 (2C), 54.5, 77.6, 86.3, 86.4, 116.3, 123.2, 123.4, 124.3, 124.4, 125.2, 125.9, 127.1, 127.3, 127.4, 127.6, 127.7, 129.7, 129.8, 131.4, 131.7, 132.9, 133.5, 136.6, 137.3, 137.4, 148.9, 153.1, 156.0, 157.5, 157.5, 161.6, 162.4 (2C), 168.5, 169.7, 172.8, 176.2, 179.4, 179.6; HRMS (FAB) calcd for C₆₆H₈₉N₁₂O₁₂S₂ (MH⁺) 1305.6164; found 1305.6160.

General procedure for the conversion of the amidoxime **13** to the amidine **14**:

Cyclo[-D-Tyr(*t*-Bu)-Arg(Pbf)-Arg(Pbf)-Nal- ψ [C(=NH)-NH]-Gly-] (14b). To a solution of amidoxime **13b** (41.7 mg, 0.0330 mmol) in MeOH (600 μ L) and AcOH (6 μ L) was added Raney Ni (440 μ L, slurry in H₂O) and the mixture was stirred under H₂ atmospheres at room temperature for 2 h. The mixture was filtered through celite. Concentration under reduced pressure followed by flash chromatography over Chromatorex with CH₂Cl₂–MeOH (95:5) gave the title compound **14b** (19.5 mg, 46% yield) as a yellow oil; $[\alpha]^{26}_D -2.79$ (*c* 0.274, DMSO); ^1H NMR (500 MHz, DMSO-*d*₆) δ 1.21 (s, 9H), 1.21–1.24 (m, 4H), 1.32–1.40 (m, 4H), 1.38 (s, 6H), 1.39 (s, 6H), 1.98 (s, 6H), 2.40 (s, 6H), 2.44 (s, 6H), 2.45–2.50 (m, 4H), 2.86–2.92 (m, 4H), 2.93 (s, 4H), 3.01–3.04 (m, 1H), 3.61–3.69 (m, 1H), 4.00–4.10 (m, 2H), 4.30 (dd, *J* = 10.5, 7.4 Hz, 1H), 4.44–4.48 (m, 1H), 6.30–6.50 (br s, 2H), 6.77 (d, *J* = 8.4 Hz, 2H), 6.78–7.00 (m, 1H), 7.01 (d, *J* = 8.4 Hz, 2H), 7.05–7.10 (m, 1H), 7.19 (d, *J* = 7.6 Hz, 1H), 7.34–7.38 (m, 2H), 7.40–7.44 (m, 1H), 7.64–7.72 (m, 1H), 7.74–7.84 (m, 2H), 8.15–8.20 (br s, 1H); ^{13}C NMR (125 MHz, DMSO-*d*₆) δ 12.3 (2C), 17.6 (2C), 17.7 (2C), 18.9 (2C), 19.0 (2C), 25.6, 28.3 (5C), 28.5 (6C), 29.1, 29.5, 40.4, 42.5 (2C), 54.2, 77.5, 79.2, 86.3, 116.3, 123.3 (2C), 124.3, 124.4 (2C), 125.3, 125.9, 127.1, 127.2, 127.3 (2C), 127.5, 128.1, 129.6 (2C), 129.7, 131.4 (2C), 131.5, 131.9, 132.7,

133.0, 134.2, 134.6, 137.2, 137.3, 153.2, 156.0, 156.1, 156.2, 157.5 (2C), 170.1, 171.0; HRMS (FAB) calcd for C₆₆H₈₉N₁₂O₁₁S₂ (MH⁺) 1289.6215; found 1289.6222.

Cyclo[-D-Tyr(t-Bu)-Arg(Pbf)-Arg(Pbf)-Nal-Gly- ψ [C(=NH)-NH]-] (14a). By use of a procedure identical with that described for the preparation of **14b** from **13b**, the amidoxime **13a** was converted into the title compound **14a** (37% yield). Yellow oil; [α]²⁷_D -4.12 (c 0.100, DMSO); ¹H NMR (500 MHz, DMSO-*d*₆) δ 0.96 (s, 9H), 0.98 (s, 3H), 1.20 (s, 3H), 1.23 (s, 3H), 1.24 (s, 3H), 1.32–1.40 (m, 8H), 1.92–2.00 (m, 6H), 2.37–2.44 (br s, 6H), 2.55 (s, 6H), 2.85–2.97 (m, 8H), 3.85–3.92 (m, 1H), 4.03–4.25 (m, 2H), 4.40–4.58 (m, 1H), 5.11 (s, 1H), 5.29 (d, *J* = 12.1 Hz, 1H), 6.29–6.46 (br s, 2H), 6.75–6.89 (br s, 1H), 6.85 (d, *J* = 8.3 Hz, 2H), 7.10 (d, *J* = 8.3 Hz, 2H), 7.32–7.44 (m, 5H), 7.68–8.85 (m, 6H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 12.1, 12.3, 17.6 (2C), 17.8 (4C), 18.9 (2C), 28.1 (2C), 28.3 (2C), 28.5, 28.5, 29.0 (4C), 29.5 (4C), 42.2 (2C), 42.5 (2C), 86.1, 86.3, 86.3, 116.3, 123.6 (2C), 123.7, 124.4 (2C), 125.8, 125.9, 127.4, 127.7 (2C), 127.8 (2C), 130.1 (2C), 131.4, 131.5 (2C), 131.8, 133.2 (2C) 134.2 (2C), 137.3 (2C), 155.0, 156.1, 157.5, 157.6, 162.3 (2C), 163.2, 170.0, 171.1, 179.4; HRMS (FAB) calcd for C₆₆H₈₉N₁₂O₁₁S₂ (MH⁺) 1289.6215; found 1289.6216.

Cyclo[-D-Tyr(t-Bu)-Arg(Pbf)-Arg(Pbf)-D-Nal- ψ [C(=NH)-NH]-Gly-] (14c). By use of a procedure identical with that described for the preparation of **14b** from **13b**, the amidoxime **13c** was converted into the title compound **14c** (35% yield). Yellow oil; [α]²⁷_D -9.02 (c 0.106, DMSO); ¹H NMR (500 MHz, DMSO-*d*₆) δ 1.20–1.30 (m, 6H), 1.22 (s, 9H), 1.23 (s, 6H), 1.34 (s, 3H), 1.36 (s, 3H), 1.39 (s, 3H), 1.40 (s, 3H), 1.50–1.52 (m, 1H), 1.62–1.67 (m, 1H), 1.99 (s, 6H), 2.40 (s, 3H), 2.43 (s, 3H), 2.84–3.00 (m, 6H), 2.94 (s, 4H), 3.00–3.07 (m, 1H), 3.11–3.17 (m, 1H), 3.62–3.74 (m, 1H), 4.02–4.17 (m, 2H), 4.27–4.35 (m, 1H), 4.45–4.51 (m, 1H), 4.52–4.61 (m, 2H), 6.29–6.51 (br s, 2H), 6.78 (d, *J* = 8.3 Hz, 2H), 7.02 (d, *J* = 8.3 Hz, 2H), 7.20 (d, *J* = 8.4 Hz, 1H), 7.34–7.40 (m, 2H), 7.42–7.46 (m, 2H) 7.65–7.74 (m, 2H), 7.56–7.83 (m, 3H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 12.3, 12.4, 17.6 (2C), 18.8 (2C), 25.0, 27.7, 28.2, 28.3 (2C), 28.5, 28.6, 28.7 (2C), 29.0, 29.3, 29.5 (2C), 30.8, 35.8, 37.0, 42.5, 45.9, 48.6 (2C), 54.6, 55.2, 77.7, 79.2, 86.3, 116.3 (2C), 123.6, 124.3 (2C), 124.4, 125.2, 125.8, 127.3, 127.4 (2C), 127.5 (2C), 128.0, 129.5, 131.4, 131.4, 131.5, 131.7, 132.9, 134.2, 136.3, 137.3, 151.1, 153.7, 155.9 (2C), 157.5 (2C), 162.4, 169.9, 171.5, 171.9, 172.5, 177.4; HRMS (FAB) calcd for C₆₆H₈₉N₁₂O₁₁S₂ (MH⁺) 1289.6215; found 1289.6223.

Cyclo[-D-Tyr(t-Bu)-Arg(Pbf)-Arg(Boc)₂- ψ [C(=NH)-NH]-Nal-Gly-] (14d). By use of a procedure identical with that described for the preparation of **14b** from **13b**, the amidoxime **13d** was converted

into the title compound **14d** (56% yield). Yellow oil; $[\alpha]^{26}_D +3.50$ (*c* 0.114, DMSO); ^1H NMR (500 MHz, DMSO-*d*₆) δ 1.13–1.22 (m, 4H), 1.23 (s, 9H), 1.37 (s, 6H), 1.39 (s, 9H), 1.47 (s, 9H), 1.50–1.62 (m, 4H), 1.99 (s, 3H), 2.42 (s, 3H), 2.49 (s, 3H), 2.81–2.90 (m, 4H), 2.90 (s, 2H), 3.00–3.18 (m, 4H) 3.24–3.31 (m, 2H), 3.46–3.63 (m, 1H), 4.11–4.16 (m, 1H), 4.37–4.49 (m, 1H), 4.49–4.60 (m, 1H), 6.80 (d, *J* = 8.4 Hz, 2H), 7.05 (d, *J* = 8.4 Hz, 2H), 7.29–7.36 (m, 1H), 7.36–7.49 (m, 2H), 7.62 (s, 1H), 7.72–7.86 (m, 3H), 8.10–8.28 (m, 2H) ^{13}C NMR (125 MHz, DMSO-*d*₆) δ 12.1 (2C), 17.6, 19.0 (2C), 25.1 (2C), 27.5, 27.6, 27.7, 28.0 (2C), 28.2 (3C), 28.5 (3C), 30.7 (4C), 35.7, 42.5 (3C), 78.1, 79.0, 82.9 (2C), 86.2, 114.4, 123.3 (2C), 124.2 (2C), 125.8 (3C), 127.4 (4C), 127.5 (2C), 127.8, 129.4 (3C), 129.6, 131.4 (2C), 131.7 (2C), 132.9, 153.2, 157.0 (2C), 157.2 (2C), 162.1 (2C), 163.1, 164.0; HRMS (FAB) calcd for C₆₃H₈₉N₁₂O₁₂S (MH⁺) 1237.6444; found 1237.6438.

Cyclo[-D-Tyr(*t*-Bu)-Arg(Boc)₂- ψ [C(=NH)-NH]-Arg(Pbf)-Nal-Gly-] (14e). By use of a procedure identical with that described for the preparation of **14b** from **13b**, the amidoxime **13e** was converted into the title compound **14e** (26% yield). Yellow oil; $[\alpha]^{27}_D -4.21$ (*c* 0.491, DMSO); ^1H NMR (500 MHz, DMSO-*d*₆) δ 1.21–1.23 (m, 4H), 1.23 (s, 9H), 1.36 (s, 6H), 1.39 (s, 9H), 1.46 (s, 9H), 1.46–1.52 (m, 4H), 1.99 (s, 3H), 2.42 (s, 3H), 2.48 (s, 3H), 2.72–2.90 (m, 4H), 2.91 (s, 2H), 3.00–3.12 (m, 2H), 3.15–3.30 (m, 2H), 3.50–3.55 (m, 1H), 3.58–3.64 (m, 1H), 4.12–4.23 (m, 1H), 4.37–4.47 (m, 2H), 4.49–4.60 (m, 1H), 6.80 (d, *J* = 8.4 Hz, 2H), 7.05 (d, *J* = 8.4 Hz, 2H), 7.33 (d, *J* = 8.2 Hz, 1H), 7.37–7.46 (m, 2H), 7.63 (s, 1H), 7.73–7.83 (m, 2H), 8.12–8.27 (m, 3H); ^{13}C NMR (125 MHz, DMSO-*d*₆) δ 12.2 (2C), 17.6, 18.9 (2C), 25.1 (2C), 27.6 (2C), 27.7, 28.0 (2C), 28.2 (3C), 28.5 (3C), 30.7 (5C), 35.7, 42.5 (2C), 78.1, 79.1, 82.9, 86.2 (2C), 114.4, 123.3 (2C), 124.2 (2C), 125.8 (2C), 127.4 (3C), 127.5 (3C), 127.8 (2C), 129.4 (3C), 129.6, 131.4 (2C), 131.7 (2C), 132.9, 153.2, 157.4 (2C), 157.5, 162.3 (2C), 163.1 (2C); HRMS (FAB) calcd for C₆₃H₈₉N₁₂O₁₂S (MH⁺) 1237.6444; found 1237.6445.

Cyclo[-D-Tyr(*t*-Bu)- ψ [C(=NH)-NH]-Arg(Pbf)-Arg(Pbf)-Nal-Gly-] (14f). By use of a procedure identical with that described for the preparation of **14b** from **13b**, the amidoxime **13f** was converted into the title compound **14f** (50% yield). Yellow oil; $[\alpha]^{26}_D -18.1$ (*c* 0.338, DMSO); ^1H NMR (500 MHz, DMSO-*d*₆) δ 1.18 (s, 9H), 1.23 (s, 3H), 1.25 (s, 3H), 1.34 (s, 3H), 1.35 (s, 3H), 1.36–1.40 (m, 8H), 1.98 (s, 3H), 1.99 (s, 3H), 2.40 (s, 3H), 2.42 (s, 3H), 2.45 (s, 3H), 2.49 (s, 3H), 2.81–2.89 (m, 2H), 2.91–2.95 (m, 4H), 2.94 (s, 4H), 2.97–3.05 (m, 2H), 3.51–3.60 (m, 2H), 3.75–3.95 (m, 2H), 4.26–4.31 (m, 1H), 4.55–4.65 (br s, 1H), 6.40–6.60 (br s, 2H), 6.68 (d, *J* = 7.6 Hz, 2H), 6.76–6.88 (br s, 1H), 6.91 (d, *J* = 7.6 Hz, 2H), 7.30 (d, *J* = 8.7 Hz, 1H), 7.36–7.42 (m, 2H), 7.62 (s, 1H), 7.71–7.81 (m, 4H),

8.50–8.56 (m, 1H); ^{13}C NMR (125 MHz, DMSO-*d*₆) δ 12.8 (2C), 18.1, 18.2, 19.5 (2C), 25.7, 25.8 (2C), 28.8 (3C), 28.9 (3C), 29.1 (5C), 29.2 (2C), 30.0, 30.1, 37.3, 43.0 (2C), 55.7, 78.0, 79.7, 86.8, 116.7, 116.8, 123.6 (2C), 124.9 (2C), 125.0, 125.9 (2C), 126.5, 127.8 (2C), 127.9, 128.1 (2C), 130.1, 131.9 (4C), 132.3 (4C), 133.4, 134.7, 135.5, 137.8, 153.8, 156.7 (2C), 158.0 (2C), 171.8, 173.2; HRMS (FAB) calcd for C₆₆H₈₉N₁₂O₁₁S₂ (MH⁺) 1289.6215; found 1289.6215.

Cyclo[-Tyr(*t*-Bu)-ψ[C(=NH)-NH]-Arg(Pbf)-Arg(Pbf)-Nal-Gly-] (14g). By use of a procedure identical with that described for the preparation of **14b** from **13b**, the amidoxime **13g** was converted into the title compound **14g** (36% yield). Yellow oil; $[\alpha]^{27}\text{D}$ -11.2 (*c* 0.108, DMSO); ^1H NMR (500 MHz, DMSO-*d*₆) δ 1.24 (s, 6H), 1.25 (s, 9H), 1.26–1.38 (m, 8H), 1.39 (s, 6H), 1.45–1.62 (m, 2H), 2.00 (s, 6H), 2.43 (s, 6H), 2.82–2.93 (m, 1H), 3.00–3.14 (m, 1H), 3.16–3.40 (m, 4H), 3.49–3.52 (m, 1H), 3.65–3.75 (m, 2H), 4.14 (t, *J* = 5.3 Hz, 2H), 4.48 (dd, *J* = 8.2, 5.3 Hz, 1H), 4.53 (dd, *J* = 7.8, 4.5 Hz, 2H), 6.29–6.52 (m, 2H), 6.83 (d, *J* = 8.2 Hz, 2H), 6.83–6.84 (m, 2H), 7.12 (d, *J* = 8.2 Hz, 2H), 7.12–7.19 (br s, 1H), 7.33–7.45 (m, 2H), 7.58–7.82 (m, 5H); ^{13}C NMR (125 MHz, DMSO-*d*₆) δ 12.3, 12.4, 17.6, 17.7, 18.9, 19.1, 28.3, 28.3 (3C), 28.3 (4C), 28.6 (4C), 28.7, 29.6 (4C), 30.9, 35.9, 42.5 (2C), 49.2, 77.6, 86.4, 86.4, 116.4, 123.3, 123.5, 124.4 (2C), 124.6, 125.3, 125.9, 127.2, 127.4, 127.5, 127.6, 127.7, 129.8, 129.9, 131.5, 131.8, 132.9, 133.6, 136.7, 137.4, 149.1, 153.1, 156.1, 157.5, 157.6, 161.7 (2C), 162.4, 168.6, 169.8, 172.9, 176.3, 179.5, 179.6; HRMS (FAB) calcd for C₆₆H₈₉N₁₂O₁₁S₂ (MH⁺) 1289.6215; found 1289.6223.

General procedure for final deprotection: *Cyclo[-D-Tyr-Arg-Arg-Nal-ψ[C(=NH)-NH]-Gly-] (15b).* The protected amidine **14b** (19.5 mg, 0.015 mmol) was treated with 1M TMSBr–thioanisole in TFA (1 mL) in the presence of *m*-cresol (10 μL) and 1,2-ethanedithiol (50 μL) at 4 °C for 15 min. The mixture was poured into ice-cold dry Et₂O (10 mL). The resulting powder was collected by centrifugation and the washed three times with ice-cold dry Et₂O. The crude product was purified by preparative HPLC to afford the expected peptide **15b** as a white powder (3.6 mg, 0.0050 mmol, 33% yield): $[\alpha]^{26}\text{D}$ -67.7 (*c* 0.132, DMSO); ^1H NMR (500 MHz, DMSO-*d*₆) δ 1.08–1.27 (m, 2H), 1.22–1.40 (m, 2H), 1.51–1.68 (m, 2H), 1.71–1.86 (m, 1H), 2.74 (dd, *J* = 13.8, 7.4 Hz, 1H), 2.82 (dd, *J* = 13.8, 8.2 Hz, 1H), 2.98 (br s, 1H), 3.35–3.52 (m, 4H), 3.94–4.07 (m, 3H), 4.12 (dd, *J* = 15.4, 7.7 Hz, 1H), 4.24 (dd, *J* = 14.2, 7.4 Hz, 1H), 4.71 (dd, *J* = 15.4, 7.2 Hz, 1H), 6.66 (d, *J* = 8.4 Hz, 2H), 6.80–7.40 (br s, 4H), 6.99 (d, *J* = 8.4 Hz, 2H), 7.42 (d, *J* = 8.4 Hz, 1H), 7.44–7.54 (m, 2H), 7.55–7.63 (m, 2H), 7.74 (s, 1H), 7.83 (d, *J* = 7.3 Hz, 1H), 7.88 (d, *J* = 8.4 Hz, 2H), 8.37 (d, *J* = 8.4 Hz, 1H), 8.42 (d, *J* = 7.6 Hz, 1H), 8.96 (d, *J* = 6.2 Hz, 1H), 9.03 (br s, 1H), 9.22 (s, 1H), 9.25 (s, 1H), 9.57 (s, 1H); ^{13}C NMR (125 MHz, DMSO-*d*₆) δ 24.8 (2C),

27.9, 28.0, 34.9, 35.2, 44.4, 52.8, 52.9, 53.8 (2C), 56.3 (2C), 115.1 (2C), 125.9, 126.3, 127.0, 127.4, 127.5, 127.6, 128.1, 130.0 (2C), 130.1, 132.0, 132.9, 134.0, 156.0, 156.7, 156.8, 158.6, 167.1, 167.8, 170.8, 171.3; HRMS (FAB) calcd for $C_{36}H_{49}N_{12}O_5$ (MH^+) 729.3949; found 729.3948.

Cyclo[-D-Tyr-Arg-Arg-Nal-Gly- ψ [C(=NH)-NH]-] (15a). By use of a procedure identical with that described for the preparation of **15b** from **14b**, the protected amidine **14a** was converted into the title compound **15a** (18% yield). $[\alpha]^{26}_D -40.0$ (c 0.140, DMSO); 1H NMR (500 MHz, DMSO- d_6) δ 1.18–1.40 (m, 4H), 1.42–1.62 (m, 4H), 2.79 (dd, J = 13.0, 8.9 Hz, 1H), 2.89 (dd, J = 13.5, 5.0 Hz, 1H), 2.95–3.07 (m, 5H), 3.17 (dd, J = 13.2, 8.2 Hz, 1H), 3.74–3.82 (m, 2H), 4.05–4.17 (m, 2H), 4.31 (dd, J = 14.2, 8.0 Hz, 1H), 4.42 (dd, J = 14.4, 7.2 Hz, 1H), 6.65 (d, J = 8.3 Hz, 2H), 6.73–7.50 (br s, 4H), 7.00 (d, J = 8.3 Hz, 2H), 7.34 (d, J = 8.3 Hz, 1H), 7.44–7.51 (m, 2H), 7.53–7.59 (m, 2H), 7.63 (br s, 1H), 7.78–7.89 (m, 4H), 8.33–8.39 (m, 1H), 8.44 (d, J = 7.2 Hz, 1H), 8.62 (d, J = 5.2 Hz, 1H), 8.85 (d, J = 7.0 Hz, 1H), 9.10 (s, 1H), 9.25 (s, 1H), 9.60 (s, 1H); ^{13}C NMR (125 MHz, DMSO- d_6) δ 25.0 (2C), 29.1 (2C), 31.3 (2C), 52.9, 56.6, 58.9 (2C), 109.5 (2C), 112.4, 115.4, 125.1, 126.1, 127.3, 127.3, 127.5, 127.7, 127.7, 128.9, 130.1, 131.8, 132.9, 135.6, 156.5, 156.7, 156.9, 169.7, 171.5, 172.3, 174.3, 175.2, 176.4, 177.1; HRMS (FAB) calcd for $C_{36}H_{49}N_{12}O_5$ (MH^+) 729.3949; found 729.3947.

Cyclo[-D-Tyr-Arg-Arg-D-Nal- ψ [C(=NH)-NH]-Gly-] (15c). By use of a procedure identical with that described for the preparation of **15b** from **14b**, the protected amidine **14c** was converted into the title compound **15c** (33% yield). $[\alpha]^{26}_D +18.4$ (c 0.126, DMSO); 1H NMR (500 MHz, DMSO- d_6) δ 1.12–1.21 (m, 1H), 1.21–1.28 (m, 2H), 1.28–1.42 (m, 2H), 1.45–1.56 (m, 1H), 1.58–1.66 (m, 1H), 1.66–1.76 (m, 1H), 2.70–2.85 (m, 2H), 3.15–3.29 (m, 3H), 3.86 (dd, J = 15.7, 4.4 Hz, 1H), 3.97–4.04 (m, 1H), 4.04–4.14 (m, 2H), 4.21 (dd, J = 14.6, 7.3 Hz, 1H), 4.84 (dd, J = 14.6, 7.9 Hz, 1H), 6.66 (d, J = 8.4 Hz, 2H), 6.70–7.50 (br s, 4H), 6.99 (d, J = 8.4 Hz, 2H), 7.35 (d, J = 5.9 Hz, 1H), 7.39 (dd, J = 8.6, 1.6 Hz, 1H), 7.46–7.53 (m, 3H), 7.56 (t, J = 5.9 Hz, 1H), 7.72 (s, 1H), 7.82–7.89 (m, 3H), 8.47 (d, J = 8.3 Hz, 1H), 8.65 (d, J = 6.2 Hz, 1H), 8.72 (d, J = 6.4 Hz, 1H), 8.89 (s, 1H), 9.17 (s, 1H), 9.25 (s, 1H), 9.48 (s, 1H); ^{13}C NMR (125 MHz, DMSO- d_6) δ 24.9, 25.0 (2C), 28.4 (2C), 28.5, 53.1 (2C), 53.5 (2C), 53.5, 54.1, 56.2, 115.0 (2C), 126.3, 127.1, 127.2, 127.5, 127.5 (2C), 128.0, 130.0 (2C), 132.9 (2C), 133.2 (2C), 156.0, 156.7, 156.8, 166.6, 168.6, 170.0, 171.3, 171.8; HRMS (FAB) calcd for $C_{36}H_{49}N_{12}O_5$ (MH^+) 729.3949; found 729.3948.

Cyclo[-D-Tyr-Arg-Arg- ψ [C(=NH)-NH]-Nal-Gly-] (15d). By use of a procedure identical with that described for the preparation of **15b** from **14b**, the protected amidine **14d** was converted into the title

compound **15d** (18% yield). $[\alpha]^{26}_D -60.0$ (*c* 0.101, DMSO); ^1H NMR (500 MHz, DMSO-*d*₆) δ 1.15–1.26 (m, 1H), 1.28–1.49 (m, 4H), 1.52–1.74 (m, 3H), 2.68–2.81 (m, 2H), 2.98–3.16 (m, 3H), 3.43–3.53 (m, 1H), 3.65 (dd, *J* = 15.8, 7.2 Hz, 1H), 3.79–3.87 (m, 1H), 4.23 (dd, *J* = 14.0, 6.5 Hz, 1H), 4.54 (dd, *J* = 14.5, 7.7 Hz, 1H), 4.76 (dd, *J* = 16.5, 7.7 Hz, 1H), 6.63 (d, *J* = 8.4 Hz, 2H), 6.87 (d, *J* = 8.4 Hz, 2H), 6.88–7.40 (br s, 4H), 7.39–7.53 (m, 3H), 7.56–7.62 (m, 1H), 7.70–7.76 (m, 1H), 7.76 (s, 1H), 7.79–7.89 (m, 3H), 8.19 (d, *J* = 8.7 Hz, 1H), 8.36 (d, *J* = 4.4 Hz, 1H), 8.68 (t, *J* = 5.7 Hz, 1H), 9.20 (s, 1H), 9.31 (s, 1H); ^{13}C NMR (125 MHz, DMSO-*d*₆) δ 25.0 (2C), 26.1, 27.5, 29.6, 35.9, 37.2, 43.7, 50.2, 54.7, 54.9, 56.5 (2C), 115.0 (2C), 125.8, 126.2, 126.9, 127.4, 127.5, 127.6, 127.9, 128.1, 130.1 (2C), 132.0, 132.8, 133.0, 155.9, 156.8, 156.8, 158.3, 165.8, 168.7, 171.1, 171.5; HRMS (FAB) calcd for C₃₆H₄₉N₁₂O₅ (MH⁺) 729.3949; found 729.3948.

Cyclo[-D-Tyr-Arg- ψ [C(=NH)-NH]-Arg-Nal-Gly-] (15e). By use of a procedure identical with that described for the preparation of **15b** from **14b**, the protected amidine **14e** was converted into the title compound **15e** (53% yield). $[\alpha]^{26}_D -41.5$ (*c* 0.133, DMSO); ^1H NMR (500 MHz, DMSO-*d*₆) δ 1.23 (s, 1H), 1.26–1.37 (m, 2H), 1.38–1.47 (m, 1H), 1.52–1.68 (m, 2H), 1.73–1.83 (m, 1H), 2.71–2.82 (m, 2H), 3.01–3.13 (m, 4H), 3.17 (dd, *J* = 13.4, 8.2 Hz, 1H), 3.46 (dd, *J* = 15.7, 4.7 Hz, 1H), 3.76 (dd, *J* = 16.0, 7.3 Hz, 1H), 4.15–4.22 (m, 1H), 4.25–4.34 (m, 2H), 4.41 (dd, *J* = 14.6, 7.3 Hz, 1H), 6.65 (d, *J* = 8.3 Hz, 2H), 6.90 (d, *J* = 8.3 Hz, 2H), 6.91–7.30 (br s, 4H), 7.36 (d, *J* = 8.4 Hz, 1H), 7.44–7.55 (m, 3H), 7.61–7.74 (m, 3H), 7.81–7.90 (m, 3H), 8.27–8.34 (m, 1H), 8.52 (d, *J* = 7.0 Hz, 1H), 8.59 (d, *J* = 3.6 Hz, 1H), 8.84 (d, *J* = 9.0 Hz, 1H), 9.20 (s, 1H), 9.23 (s, 1H); ^{13}C NMR (125 MHz, DMSO-*d*₆) δ 24.8 (2C), 28.1 (2C), 28.5 (2C), 52.2, 53.2, 54.4 (2C), 115.0 (2C), 126.1, 126.2, 126.9, 127.3, 127.4, 127.5 (2C), 127.8, 130.0 (2C), 131.8 (2C), 131.9, 132.9, 155.9 (2C), 156.7 (2C), 167.4, 168.0, 168.1, 168.9, 170.1, 171.4; HRMS (FAB) calcd for C₃₆H₄₉N₁₂O₅ (MH⁺) 729.3949; found 729.3944.

Cyclo[-D-Tyr- ψ [C(=NH)-NH]-Arg-Arg-Nal-Gly-] (15f). By use of a procedure identical with that described for the preparation of **15b** from **14b**, the protected amidine **14f** was converted into the title compound **15f** (40% yield). $[\alpha]^{26}_D -100.9$ (*c* 0.114, DMSO); ^1H NMR (500 MHz, DMSO-*d*₆) δ 0.68–0.79 (m, 1H), 0.81–0.93 (m, 1H), 1.24–1.41 (m, 2H), 1.54–1.66 (m, 1H), 1.74–1.85 (m, 1H), 1.89–1.99 (m, 1H), 2.80–2.98 (m, 3H), 2.98–3.13 (m, 3H), 3.20–3.26 (m, 1H), 3.80 (dd, *J* = 16.4, 6.1 Hz, 1H), 3.91 (dd, *J* = 16.4, 6.1 Hz, 1H), 3.93–4.02 (m, 1H), 4.17 (dd, *J* = 15.8, 7.9 Hz, 1H), 4.45 (t, *J* = 7.9 Hz, 1H), 6.69 (d, *J* = 8.3 Hz, 2H), 6.50–7.50 (br s, 4H), 7.00 (d, *J* = 8.3 Hz, 2H), 7.38–7.50 (m, 3H), 7.51–7.57 (m, 1H), 7.62 (br s, 1H), 7.72 (s, 1H), 7.86 (m, 3H), 7.92 (d, *J* = 8.3 Hz, 1H), 8.14 (d, *J* = 8.3 Hz, 1H), 9.10 (s, 1H), 9.26 (s, 1H), 9.38 (s, 1H), 9.45 (s, 1H), 9.76 (d, *J* = 8.3 Hz, 1H); ^{13}C NMR

(125 MHz, DMSO-*d*₆) δ 25.0 (2C), 29.1 (2C), 31.3 (2C), 52.9, 56.6, 58.9 (2C), 109.5 (2C), 112.4, 115.4, 125.1, 126.1, 127.3, 127.3, 127.5, 127.7, 127.7, 128.9, 130.1, 131.8, 132.9, 135.6, 156.5, 156.7, 156.9, 169.7, 171.5, 172.3, 174.3, 175.2, 176.4, 177.1; HRMS (FAB) calcd for C₃₆H₄₉N₁₂O₅ (MH⁺) 729.3949; found 729.3939.

Cyclo[-Tyr-ψ[C(=NH)-NH]-Arg-Arg-Nal-Gly-] (15g). By use of a procedure identical with that described for the preparation of **15b** from **14b**, the protected amidine **14g** was converted into the title compound **15g** (32% yield). $[\alpha]^{26}_D +61.6$ (*c* 0.160, DMSO); ¹H NMR (500 MHz, DMSO-*d*₆) δ 1.12–1.22 (m, 1H), 1.23–1.32 (m, 1H), 1.37–1.50 (m, 2H), 1.53–1.64 (m, 2H), 1.70–1.80 (m, 1H), 1.85–1.96 (m, 1H), 2.87–2.96 (m, 2H), 2.99 (dd, *J* = 14.2, 9.0 Hz, 1H), 3.07 (dd, *J* = 13.6, 10.2 Hz, 1H), 3.11–3.18 (m, 1H), 3.85 (dd, *J* = 15.0, 7.5 Hz, 1H), 3.98 (dd, *J* = 15.0, 5.8 Hz, 1H), 4.30 (dd, *J* = 15.3, 9.2 Hz, 1H), 4.42 (td, *J* = 9.1, 5.0 Hz, 1H), 4.68 (dd, *J* = 15.1, 6.5 Hz, 1H), 6.72 (d, *J* = 8.4 Hz, 2H), 6.80–7.40 (br s, 4H), 7.09 (d, *J* = 8.4 Hz, 2H), 7.38 (dd, *J* = 8.4, 1.4 Hz, 1H), 7.43–7.50 (m, 2H), 7.53 (t, *J* = 5.5 Hz, 1H), 7.67 (s, 1H), 7.74–7.88 (m, 3H), 8.02 (d, *J* = 4.9 Hz, 1H), 8.09 (d, *J* = 8.3 Hz, 1H), 8.40 (d, *J* = 6.9 Hz, 1H), 8.50 (d, *J* = 6.4 Hz, 1H), 8.91 (d, *J* = 9.5 Hz, 1H), 9.13 (s, 1H), 9.39 (s, 1H), 9.63 (s, 1H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 25.1 (2C), 27.8 (2C), 36.1, 36.3, 53.7, 54.4, 56.4, 57.7, 115.3 (2C), 125.5, 126.0, 127.4, 127.7 (2C), 130.1 (3C), 131.8 (2C), 132.9 (3C), 135.9, 156.4, 156.7, 156.9 (2C), 159.0, 167.4, 168.3, 169.5, 170.8, 171.0; HRMS (FAB) calcd for C₃₆H₄₉N₁₂O₅ (MH⁺) 729.3949; found 729.3939.

[¹²⁵I]-SDF-1 binding and displacement. Membrane extracts were prepared from HEK293 cell lines expressing CXCR4. For ligand binding, 50 μ L of the inhibitor, 25 μ L of [¹²⁵I]-SDF-1 α (0.3 nM, Perkin-Elmer Life Sciences) and 25 μ L of the membrane/beads mixture [7.5 μ g/well of membrane, 0.5 mg/well of PVT WGA beads (Amersham)] in assay buffer (25 mM HEPES pH 7.4, 1 mM CaCl₂, 5 mM MgCl₂, 140 mM NaCl, 250 mM sucrose, 0.5% BSA) were incubated in the wells of an Optiplate places (Perkin-Elmer Life Sciences) at room temperature for 1 h. The bound radioactivity was counted for 1 min/well in a TopCount (Packard). Inhibitory activity of the test compounds was determined based on the inhibition of [¹²⁵I]-SDF-1 binding to the receptors (IC₅₀, triplicate experiments, Figure S4 and Table 1).

Determination of anti-HIV activity. The peptide sensitivity of three HIV-1 strains was determined by the MAGI assay. The target cells (HeLa-CD4/CCR5-LTR- β -gal; 104 cells/well) were plated in 96-well flat microtiter culture plates. On the following day, the cells were inoculated with the HIV-1

(60 MAGI U/well, giving 60 blue cells after 48 h of incubation) and cultured in the presence of various concentrations of the drugs in fresh medium. Forty-eight hours after viral exposure, all the blue cells stained with X-Gal (5-bromo-4-chloro-3-indolyl- β -D-galactopyranoside) were counted in each well. The activity of test compounds was determined as the concentration that blocked HIV-1 replication by 50% (50% effective concentration [EC₅₀]). EC₅₀ was determined by using the following formula:

$$EC_{50} = 10^{[\log(A/B) \times (50 - C)/(D - C) + \log(B)]},$$

wherein

- A: of the two points on the graph which bracket 50% inhibition, the higher concentration of the test compound,
- B: of the two points on the graph which bracket 50% inhibition, the lower concentration of the test compound,
- C: inhibitory activity (%) at the concentration B,
- D: inhibitory activity (%) at the concentration A.

References

- (1) Van Rompaey, K.; Van den Eynde, I.; De kimpe, N.; Tourwe, D. A versatile synthesis of 2-substituted 4-amino-1,2,4,5-tetrahydro-2-benzadepine-3-ones. *Tetrahedron* **2003**, *59*, 4421–4432.

Figure S1. HPLC analysis of (a) compound **14b**; (b) compound **14c**; (c) the mixture of compounds **14b** and **14c**. *HPLC conditions:* a linear gradient of MeCN (50-70% over 20 min), detection at 220 nm.




Figure S2. HPLC analysis of (d) compound **13f**; (e) compound **13g**; (f) the mixture of compounds **13f** and **13g**. *HPLC conditions:* a linear gradient of MeCN (50-70% over 20 min), detection at 220 nm.




Figure S3. HPLC analysis of compounds **15a–g**. *HPLC conditions:* a linear gradient of MeCN (20–35% over 15 min), detection at 220 nm.








Figure S4. The representative dose-response curves of the [^{125}I]-SDF-1 binding inhibition by FC131 analogs **15a–g** ($n = 2$). The same experiments were performed in triplicate (for IC_{50} , see Table 1).





single_pulse


















single pulse decoupled gated NOE
C:\Documents and Settings\Eriko\Inokuchi\アスカト\アノン\NMR\paper\新しいづオナルミドキシメチル\J100 R-Nal amidoxime 13C rt DMSO-1.als

```


DFILE J100 R-Nal amidoxime 13C r
COMNT single pulse decoupled gate
DATIM 29-12-2010 09:49:19
OBNUC 13C
EXMOD single_pulse dec
OBFRQ 125.77 MHz
OBSET 7.87 kHz
OBFIN 4.21 Hz
POINT 26214
FREQU 31446.06 Hz
SCANS 14435
ACQTM 0.83336 sec
PD 2.0000 sec
PW1 7.47 usec
IRNUC 1H
CTEMP 26.4 c
SLVNT DMSO
EXREF 39.50 ppm
BF 0.12 Hz
RGAIN 58


```


13d





single_pulse















single pulse decoupled gated NOE


C:\Documents and Settings\eriko_Inokuchi\My Documents\NMR\paper\新しいづオナルダツアミドキシメルチルアミド\13C DMSO110201-1.^c
single pulse decoupled 13C DMSO
L-Tyr amidoxime protected 13C
single pulse decoupled gate 02-02-2011 08:41:29
13C
single pulse decoupled
DF2FILE
F2CONT
D1T1
D1T2
D1T3
D1T4
D1T5
D1T6
D1T7
D1T8
D1T9
D1T10
D1T11
D1T12
D1T13
D1T14
D1T15
D1T16
D1T17
D1T18
D1T19
D1T20
D1T21
D1T22
D1T23
D1T24
D1T25
D1T26
D1T27
D1T28
D1T29
D1T30
D1T31
D1T32
D1T33
D1T34
D1T35
D1T36
D1T37
D1T38
D1T39
D1T40
D1T41
D1T42
D1T43
D1T44
D1T45
D1T46
D1T47
D1T48
D1T49
D1T50
D1T51
D1T52
D1T53
D1T54
D1T55
D1T56
D1T57
D1T58
D1T59
D1T60
D1T61
D1T62
D1T63
D1T64
D1T65
D1T66
D1T67
D1T68
D1T69
D1T70
D1T71
D1T72
D1T73
D1T74
D1T75
D1T76
D1T77
D1T78
D1T79
D1T80
D1T81
D1T82
D1T83
D1T84
D1T85
D1T86
D1T87
D1T88
D1T89
D1T90
D1T91
D1T92
D1T93
D1T94
D1T95
D1T96
D1T97
D1T98
D1T99
D1T100
D1T101
D1T102
D1T103
D1T104
D1T105
D1T106
D1T107
D1T108
D1T109
D1T110
D1T111
D1T112
D1T113
D1T114
D1T115
D1T116
D1T117
D1T118
D1T119
D1T120
D1T121
D1T122
D1T123
D1T124
D1T125
D1T126
D1T127
D1T128
D1T129
D1T130
D1T131
D1T132
D1T133
D1T134
D1T135
D1T136
D1T137
D1T138
D1T139
D1T140
D1T141
D1T142
D1T143
D1T144
D1T145
D1T146
D1T147
D1T148
D1T149
D1T150
D1T151
D1T152
D1T153
D1T154
D1T155
D1T156
D1T157
D1T158
D1T159
D1T160
D1T161
D1T162
D1T163
D1T164
D1T165
D1T166
D1T167
D1T168
D1T169
D1T170
D1T171
D1T172
D1T173
D1T174
D1T175
D1T176
D1T177
D1T178
D1T179
D1T180
D1T181
D1T182
D1T183
D1T184
D1T185
D1T186
D1T187
D1T188
D1T189
D1T190
D1T191
D1T192
D1T193
D1T194
D1T195
D1T196
D1T197
D1T198
D1T199
D1T200









single_pulse





single pulse decoupled gated NOE
C:\Documents and Settings\eriko_Inokuchi\My Documents\NMR\paper\新しいづオルナルダリ\Yamidine\NaI\J103 NaI amidine 13C rt DMSO-1.als
LJ103 NaI amidine 13C rt DM
single pulse decoupled gate
06-01-2011 21:14:09
13C
single pulse dec
125.77 MHz
7.87 kHz
4.21 Hz
26214
31446.06 Hz
1024
0.8336 sec
2.0000 sec
7.47 usec
CTEMP
SLVNT
DMSO
ACQTM
PD
EXREF
BF
IIRNUC 1H
RGAIN
39.004
39.166
39.328
39.500
39.523
39.562
39.574
39.622
39.662
39.695
39.834
39.996
40.006
40.416
42.466
54.246
77.501
79.170
86.257
116.264
123.342
124.324
125.278
125.850
127.090
127.195
127.348
127.472
128.149
129.580
129.704
131.440
131.516
131.888
132.737
134.158
134.607
137.258
137.296
153.206
156.058
156.135
157.479
170.137
170.976



single_pulse










single pulse decoupled gated NOE
C:\Documents and Settings\eriko_Inokuchi\デスクトップ\Inokuchi\paper\新しいづオルダ\Y-NMR\amidine\YR-Nal\J104 R-Nal amidineprotect 13C DMSO-1.als


DFILE LJI04 R-Nal amidineprotect
single pulse decoupled gate
19-01-2011 10:42:52
13C
single pulse decoupled
I25.77 MHz
7.87 kHz
4.21 Hz
EXMOD
OBFRQ
OBSET
OBFIN
POINT
26214
FREQU 31446.06 Hz
SCANS 1000
ACQTM 0.8336 sec
PD 2.0000 sec
PW1 7.47 usec
IRNUC 1H
CTEMP 25.3 c
SLVNT DMSO
EXREF 39.50 ppm
BF 0.12 Hz
RGAIN 54




C:\Documents and Settings\Eriko Inokuchi\デスクトップ\Inokuchi\paper\新论文\NMR\amidine\J105 R-R amidineprotect 1H DMSO-1.als


DF11E LJ105 R-R amidineprotect 1H
 COMNT DATIM
 OBNUC 1H
 EXMOD NON
 OBFRQ 399.65 MHz
 OBSET 124.00 kHz
 OBFIN 10500.00 Hz
 POINT 32768
 FREQU 7992.01 Hz
 SCANS 256
 ACQTM 4.1001 sec
 PD 2.9000 sec
 PW1 5.50 usec
 IRNUC 1H
 CTEMP 22.9 °C
 SLVNT DMSO
 EXREF 0.00 ppm
 BF 0.12 Hz
 RGAIN 16







single_pulse












single_pulse



single pulse decoupled gated NOE
C:\Documents and Settings\Eriko\Inokuchi\Proteins\15a\paper\新しいづオナルダマ\NMR\amide\depro\13C DMSO-1.als

DF1LE Gdpr 13C DMSO-1. als
single pulse decoupled gate
14-01-2011 17:57:57
13C
single pulse dec
I25.77 MHz
7.87 kHz
4.21 Hz
EXMOD
OBSET
OBFIN
POINT
26214
FREQU
SCANS 0.8336 sec
ACQTM 2.0000 sec
PD 7.47 usec
POINT
31446.06 Hz
I1NUC 1H
CTEMP 26.3 c
SLVNT CDCL3
EXREF 77.00 ppm
BF 0.12 Hz
RGAIN 56



single_pulse

C:\Documents and Settings\Eriko Inokuchi\¥disk\¥paper\¥Inokuchi\¥Inokuchi\¥single_pulse\¥NMR\¥amidine deprotect 1H DMSO -1.als

DFILE L178 LNal deprotect 1H DMSO

COMNT single_pulse

DATIM 04-01-2011 14:29:32

1H OBNUC single_pulse, ex2

EXMOD 500.16 MHz

OBFRQ 2.41 kHz

OBSET 6.01 Hz

OBFIN 52428

POINT 7507.39 Hz

FREQU 7507.39 Hz

SCANS 128

ACQTM 6.9835 sec

PD 5.0000 sec

PW1 6.50 usec

IRNUC 1H



CTEMP 25.8 c

SLVNT DMSO

EXREF 2.49 ppm



BF 0.12 Hz

RGAIN 42



single pulse decoupled gated NOE
C:\Documents and Settings\Eriko\Inokuchi\スクト\アリノクチ\paper\新しいづオナルダ\NMR\amide\deprotect\NaI\J78\NaI deprotect\13C DMSO -1.als


DFILE L178\NaI deprotect\13C DMSO
SCANT single pulse decoupled gate
03-01-2011 07:03:52
13C
single_pulse dec
EXMOD DBFRO
125.77 MHz
7.87 kHz
4.21 Hz
OBSET
OBFIN
POINT 26214
FREQU 31446.06 Hz
SCANS 16384
ACQTM 0.8336 sec
PD 2.0000 sec
PW1 7.47 usec
IRNUC 1H
CTEMP 25.3 c
SLVNT DMSO
EXREF 39.50 ppm
BF 0.12 Hz
RGAIN 58





```

C:\Documents and Settings\Eriko Inokuchi\デスクトップ\Inokuchi paper\新しいファイル\J93 DNaI depro 1H DMSO-1.a
DFILE LJ93 DNaI depro 1H DMSO-1.a
COMNT single pulse
DATA 1.4, 2.0, 1.0, 1.3, 5.4

```





single pulse decoupled gated NOE
C:\Documents and Settings\eriko_Inokuchi\My Documents\Inokuchi\Ypaper\新しいづオルダマニド\NMR\yamidine depro\DNal\J93 DNal depro 13C DMSO-1.
DFILE LJ93.DNal depro 13C DMSO-1.
COMNT single pulse decoupled gate
DATIM 14-01-2011 13:16:11
QBNUC 13C
EXMOD single_pulse dec
OBFRQ 125.77 MHz
OBSET 7.87 kHz
OBFIN 4.21 Hz
POINT 26214
FREQU 31446.06 Hz
SCANS 1024
ACQTM 0.8336 sec
PD 2.0000 sec
PW1 7.47 usec
IRNUC 1H
CTEMP 25.8 c
SLVNT DMSO
EXREF 39.50 ppm
BF 0.12 Hz
RGAIN 56




single_pulse






C:\Documents and Settings\Eriko Inokuchi\デスクトップ\Inokuchi¥paper¥新しいフルダッシュNMR\amidine depro\Y-NalJ94 R-Nal 1H rt DMSO-1.als
 single_pulse
 13-01-2011 13:22:27
 1H
 OBNUC
 EXMOD
 500.16 MHz
 OBFRQ 2.41 kHz
 OBSET 6.01 Hz
 OBFIN 52428
 POINT 52428
 FREQU 7507.39 Hz
 SCANS 256
 ACQTM 6.9835 sec
 PD 5.0000 sec
 PW1 6.50 usec
 IRNUC 1H
 CTEMP 24.3 c
 SLVNT DMSO
 EXREF 2.49 ppm
 BF 0.12 Hz
 RGAIN 44










single pulse decoupled gated NOE
C:\Documents and Settings\Eriko\Inokuchi\アスカトツ\Inokuchi\paper\新しいづオルダ\NMR\amidine depro\¥R\J95 R-Rdepro 13C DMSO 110119-1.als
DFILE L195 R-Rdepro 13C DMSO 1101
COMNT single pulse decoupled gate
DATIM 20-01-2011 07:57:59
13C
OBNUC single pulse dec
EXMOD 125.77 MHz
OBFRQ 7.87 kHz
OBSET 4.21 Hz
OBFIN 26214
POINT 31446, 06 Hz
FREQU SCANS 12000
ACQTM 0.8336 sec
PD 2.0000 sec
PW1 7.47 usec
IRNUC 1H
CTEMP 26.0 c
SLVNT DMSO
EXREF 39.50 ppm
BF 0.12 Hz
RGAIN 56




single_pulse



single pulse decoupled gated NOE
C:\Documents and Settings\eriko_Inokuchi\スクト\新しいづオルダ\NMR\amidine depro\DTyr\J77 DTyrdopro 13C rt DMSO-1.als
DTyrdopro 13C rt DMSO-1.als
DTFILE LJ77 DTyrdopro 13C rt DMSO-1.als
COMNT single pulse decoupled gate
DATIM 07-01-2011 08:17:35
OBNUC 13C
EXMOD single pulse dec
OBFRQ 125.77 MHz
OBSET 7.87 kHz
OBFIN 4.21 Hz
POINT 26214
FREQU 31446.06 Hz
SCANS 12288
ACQTM 0.8336 sec
PD 2.0000 sec
PW1 3.73 usec
IRNUC 1H
CTEMP 27.0 c
SLVNT DMSO
EXREF 39.50 ppm
BF 0.12 Hz
RGAIN 58





single pulse decoupled gated NOE
C:\Documents and Settings\eriko_Inokuchi\デスクトップ\Inokuchi\paper\新しいづオルダ\NMR\amidine depro\Tyr\J92LTyrdopro 13C DMSO-1.als
DFILE LJ92LTyrdopro 13C DMSO-1.als
COMNT single pulse decoupled gate
DATIM 14-01-2011 17:57:57
OBNUC 13C
single pulse dec
EXMOD
I25.77 MHz
OBFRQ 7.87 kHz
OBSET 4.21 Hz
OBFIN
POINT 26214
FREQU 31446.06 Hz
SCANS 1925
ACQTM 0.8336 sec
PD 2.0000 sec
PW1 7.47 usec
IRNUC 1H
CTEMP 26.3 c
SLVNT CDCL3
EXREF 39.52 ppm
BF 0.12 Hz
RGAIN 56

